Combining designer receptors exclusively activated by designer drugs and neuroimaging in experimental models: A powerful approach towards neurotheranostic applications

The combination of chemogenetics targeting specific brain cell populations with in vivo imaging techniques provides scientists with a powerful new tool to study functional neural networks at the whole‐brain scale. A number of recent studies indicate the potential of this approach to increase our understanding of brain function in health and disease. In this review, we discuss the employment of a specific chemogenetic tool, designer receptors exclusively activated by designer drugs, in conjunction with non‐invasive neuroimaging techniques such as PET and MRI. We highlight the utility of using this multiscale approach in longitudinal studies and its ability to identify novel brain circuits relevant to behaviour that can be monitored in parallel. In addition, some identified shortcomings in this technique and more recent efforts to overcome them are also presented. Finally, we discuss the translational potential of designer receptors exclusively activated by designer drugs in neuroimaging and the promise it holds for future neurotheranostic applications.

[1]  B. Roth.  DREADDs for Neuroscientists , 2016, Neuron.

[2]  Jacob M. Hooker,et al.  Salvinorin A and derivatives: Protection from metabolism does not prolong short-term, whole-brain residence , 2009, Neuropharmacology.

[3]  Joanna L. Sharman,et al.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands , 2015, Nucleic Acids Res..

[4]  Pratima Chowdary,et al.  Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. , 2011, The New England journal of medicine.

[5]  Reid H. J. Olsen,et al.  Cre‐dependent DREADD (Designer Receptors Exclusively Activated by Designer Drugs) mice , 2016, Genesis.

[6]  Michael J. Krashes,et al.  Gs-coupled GPCR signalling in AgRP neurons triggers sustained increase in food intake , 2016, Nature Communications.

[7]  T. Daigle,et al.  A Gαs DREADD Mouse for Selective Modulation of cAMP Production in Striatopallidal Neurons , 2013, Neuropsychopharmacology.

[8]  Anirvan Ghosh,et al.  Identification of a Corticohabenular Circuit Regulating Socially Directed Behavior , 2017, Biological Psychiatry.

[9]  B. Roth,et al.  Behavioral and Physiological Effects of a Novel Kappa-Opioid Receptor-Based DREADD in Rats , 2016, Neuropsychopharmacology.

[10]  M. Nitsche,et al.  Safety and Tolerability , 2020, Definitions.

[11]  V. Gradinaru,et al.  Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems , 2017, Nature Neuroscience.

[12]  Kim David Ferrari,et al.  Rapid Reconfiguration of the Functional Connectome after Chemogenetic Locus Coeruleus Activation , 2019, Neuron.

[13]  B. Richmond,et al.  Multimodal Imaging for DREADD-Expressing Neurons in Living Brain and Their Application to Implantation of iPSC-Derived Neural Progenitors , 2016, The Journal of Neuroscience.

[14]  Christopher Southan,et al.  THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels , 2019, British journal of pharmacology.

[15]  B. Oldfield,et al.  The Role of Mesolimbic Reward Neurocircuitry in Prevention and Rescue of the Activity-Based Anorexia (ABA) Phenotype in Rats , 2017, Neuropsychopharmacology.

[16]  Michael Michaelides,et al.  Impaired periamygdaloid-cortex prodynorphin is characteristic of opiate addiction and depression. , 2013, The Journal of clinical investigation.

[17]  Steven P. Wilson,et al.  Designer Receptors Show Role for Ventral Pallidum Input to Ventral Tegmental Area in Cocaine Seeking , 2014, Nature Neuroscience.

[18]  Thomas E Prisinzano,et al.  Role of Ventral Subiculum in Context-Induced Relapse to Alcohol Seeking after Punishment-Imposed Abstinence , 2016, The Journal of Neuroscience.

[19]  Richard C Saunders,et al.  Chemogenetic disconnection of monkey orbitofrontal and rhinal cortex reversibly disrupts reward value , 2015, Nature Neuroscience.

[20]  M. Jann,et al.  Rapid formation of clozapine in guinea-pigs and man following clozapine-N-oxide administration. , 1994, Archives internationales de pharmacodynamie et de therapie.

[21]  Pedro Rosa-Neto,et al.  PET imaging of freely moving interacting rats , 2019, NeuroImage.

[22]  Thomas Wichmann,et al.  Metabolism and Distribution of Clozapine-N-oxide: Implications for Nonhuman Primate Chemogenetics. , 2017, ACS chemical neuroscience.

[23]  Xi-Ping Huang,et al.  A New DREADD Facilitates the Multiplexed Chemogenetic Interrogation of Behavior , 2015, Neuron.

[24]  Bryan L. Roth,et al.  Modulation of the autonomic nervous system and behaviour by acute glial cell Gq protein‐coupled receptor activation in vivo , 2013, The Journal of physiology.

[25]  S. Duval,et al.  Modulation of the autonomic nervous system assessed through heart rate variability by a mindfulness based stress reduction program. , 2014, International journal of cardiology.

[26]  Marleen Verhoye,et al.  Chemogenetic silencing of neurons in the mouse anterior cingulate area modulates neuronal activity and functional connectivity , 2019, NeuroImage.

[27]  Robert M Sears,et al.  Stimulation‐induced transient changes in neuronal activity, blood flow and N‐acetylaspartate content in rat prefrontal cortex: a chemogenetic fMRS‐BOLD study , 2016, NMR in biomedicine.

[28]  Willem M. Otte,et al.  A novel approach to map induced activation of neuronal networks using chemogenetics and functional neuroimaging in rats: A proof-of-concept study on the mesocorticolimbic system , 2017, NeuroImage.

[29]  Olli Gröhn,et al.  Functional connectivity under six anesthesia protocols and the awake condition in rat brain , 2018, NeuroImage.

[30]  D. Kullmann,et al.  Olanzapine: A potent agonist at the hM4D(Gi) DREADD amenable to clinical translation of chemogenetics , 2019, Science Advances.

[31]  Gord Fishell,et al.  Reverse Pharmacogenetic Modulation of the Nucleus Accumbens Reduces Ethanol Consumption in a Limited Access Paradigm , 2014, Neuropsychopharmacology.

[32]  Damien A. Fair,et al.  The Rhesus Monkey Connectome Predicts Disrupted Functional Networks Resulting from Pharmacogenetic Inactivation of the Amygdala , 2016, Neuron.

[33]  Prachi Khare,et al.  Clozapine N-Oxide Administration Produces Behavioral Effects in Long–Evans Rats: Implications for Designing DREADD Experiments , 2016, eNeuro.

[34]  Christopher Southan,et al.  THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes , 2019, British journal of pharmacology.

[35]  Alasdair J. G. Gray,et al.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY , 2017, Nucleic Acids Res..

[36]  N. Volkow,et al.  Whole-brain circuit dissection in free-moving animals reveals cell-specific mesocorticolimbic networks. , 2013, The Journal of clinical investigation.

[37]  Alessandro Gozzi,et al.  Brainwide mapping of endogenous serotonergic transmission via chemogenetic-fMRI , 2017, bioRxiv.

[38]  B. Roth,et al.  Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand , 2007, Proceedings of the National Academy of Sciences.

[39]  Christopher Southan,et al.  THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Transporters , 2019, British journal of pharmacology.

[40]  J. Bennett,et al.  The Status of RPE65 Gene Therapy Trials: Safety and Efficacy. , 2015, Cold Spring Harbor perspectives in medicine.

[41]  M. Verhoye,et al.  Hypersynchronicity in the default mode-like network in a neurodevelopmental animal model with relevance for schizophrenia , 2019, Behavioural Brain Research.

[42]  Roger A. H. Adan,et al.  Combined Use of the Canine Adenovirus-2 and DREADD-Technology to Activate Specific Neural Pathways In Vivo , 2014, PloS one.

[43]  J. Pratte,et al.  Simultaneous assessment of rodent behavior and neurochemistry using a miniature positron emission tomograph , 2011, Nature Methods.

[44]  Chemogenetic ligands for translational neurotheranostics , 2018 .

[45]  Arthur Christopoulos,et al.  THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein‐coupled receptors , 2019, British journal of pharmacology.

[46]  D. Kätzel,et al.  Pharmacokinetic and pharmacodynamic actions of clozapine-N-oxide, clozapine, and compound 21 in DREADD-based chemogenetics in mice , 2019, Scientific Reports.

[47]  G. Ronzitti,et al.  Emerging Issues in AAV-Mediated In Vivo Gene Therapy , 2017, Molecular therapy. Methods & clinical development.

[48]  Yasuyuki Kimura,et al.  PET imaging-guided chemogenetic silencing reveals a critical role of primate rostromedial caudate in reward evaluation , 2016, Nature Communications.

[49]  S. Rumpel,et al.  Analysis of Transduction Efficiency, Tropism and Axonal Transport of AAV Serotypes 1, 2, 5, 6, 8 and 9 in the Mouse Brain , 2013, PloS one.

[50]  J. Wess,et al.  Engineering GPCR signaling pathways with RASSLs , 2008, Nature Methods.

[51]  Jian Hua Li,et al.  A chemical-genetic approach to study G protein regulation of β cell function in vivo , 2009, Proceedings of the National Academy of Sciences.

[52]  W. Jagust,et al.  Safety and tolerability of putaminal AADC gene therapy for Parkinson disease , 2009, Neurology.

[53]  M. Michaelides,et al.  Ultrapotent chemogenetics for research and potential clinical applications , 2019, Science.

[54]  M. Walton,et al.  Time-dependent assessment of stimulus-evoked regional dopamine release , 2019, Nature Communications.

[55]  Reid H. J. Olsen,et al.  DREADD Agonist 21 Is an Effective Agonist for Muscarinic-Based DREADDs in Vitro and in Vivo , 2018, ACS pharmacology & translational science.

[56]  M. Michaelides,et al.  DREAMM: A Biobehavioral Imaging Methodology for Dynamic In Vivo Whole-Brain Mapping of Cell Type-Specific Functional Networks , 2015, Neuropsychopharmacology.

[57]  Valerio Zerbi,et al.  Cortical excitation:inhibition imbalance causes network-specific functional hypoconnectivity: a DREADD-fMRI study , 2018 .

[58]  M. Nicolelis,et al.  Remote Control of Neuronal Activity in Transgenic Mice Expressing Evolved G Protein-Coupled Receptors , 2009, Neuron.

[59]  Brandon K. Harvey,et al.  Chemogenetics revealed: DREADD occupancy and activation via converted clozapine , 2017, Science.

[60]  M. Jann,et al.  Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients , 1998, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[61]  B. Roth,et al.  Transient neuronal inhibition reveals opposing roles of indirect and direct pathways in sensitization , 2010, Nature Neuroscience.

[62]  S. Hattar,et al.  Eye-Drops for Activation of DREADDs , 2017, Front. Neural Circuits.

[63]  K. Deisseroth.  Optogenetics: 10 years of microbial opsins in neuroscience , 2015, Nature Neuroscience.

[64]  B. Roth,et al.  DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility. , 2015, Annual review of pharmacology and toxicology.

[65]  S. Robinson,et al.  Chemogenetic Silencing of Neurons in Retrosplenial Cortex Disrupts Sensory Preconditioning , 2014, The Journal of Neuroscience.

[66]  Dipendra K. Aryal,et al.  Elucidation of The Behavioral Program and Neuronal Network Encoded by Dorsal Raphe Serotonergic Neurons , 2016, Neuropsychopharmacology.

[67]  Hyunah Choo,et al.  The First Structure–Activity Relationship Studies for Designer Receptors Exclusively Activated by Designer Drugs , 2015, ACS chemical neuroscience.